miR-145-5p inhibits tumor occurrence and metastasis through the NF-κB signaling pathway by targeting TLR4 in malignant melanoma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
miR-145-5p inhibits tumor occurrence and metastasis through the NF-κB signaling pathway by targeting TLR4 in malignant melanoma
Authors
Keywords
-
Journal
JOURNAL OF CELLULAR BIOCHEMISTRY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-01-31
DOI
10.1002/jcb.28388
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MicroRNA-145 attenuates high glucose-induced oxidative stress and inflammation in retinal endothelial cells through regulating TLR4/NF-κB signaling
- (2018) Ying Hui et al. LIFE SCIENCES
- MicroRNA-143-3p inhibits growth and invasiveness of melanoma cells by targeting cyclooxygenase-2 and inversely correlates with malignant melanoma progression
- (2018) Elisabetta Panza et al. BIOCHEMICAL PHARMACOLOGY
- miR-145-5p Suppresses Tumor Cell Migration, Invasion and Epithelial to Mesenchymal Transition by Regulating the Sp1/NF-κB Signaling Pathway in Esophageal Squamous Cell Carcinoma
- (2017) Li-Li Mei et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Continued Increase in Melanoma Incidence across all Socioeconomic Status Groups in California, 1998–2012
- (2017) Christina A. Clarke et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Towards therapeutic advances in melanoma management: An overview
- (2017) Swarnendra Singh et al. LIFE SCIENCES
- Recurrence behavior in early-stage cutaneous melanoma
- (2017) Faruk Tas et al. MELANOMA RESEARCH
- MicroRNA dysregulation in melanoma
- (2016) Nicholas Latchana et al. SURGICAL ONCOLOGY-OXFORD
- Autophagy facilitates TLR4- and TLR3-triggered migration and invasion of lung cancer cells through the promotion of TRAF6 ubiquitination
- (2014) Zhenzhen Zhan et al. Autophagy
- microRNAs in Cancer: Lessons from Melanoma
- (2014) Eyal Greenberg et al. CURRENT PHARMACEUTICAL DESIGN
- Toll-Like Receptor 4 Signaling Promotes the Migration of Human Melanoma Cells
- (2014) Yuko Takazawa et al. TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
- miR-145 overexpression suppresses the migration and invasion of metastatic melanoma cells
- (2013) PETER DYNOODT et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Roles of toll-like receptors in Cancer: A double-edged sword for defense and offense
- (2012) Shaherin Basith et al. ARCHIVES OF PHARMACAL RESEARCH
- MicroRNAs in Stress Signaling and Human Disease
- (2012) Joshua T. Mendell et al. CELL
- NF-κB regulation: lessons from structures
- (2012) Gourisankar Ghosh et al. IMMUNOLOGICAL REVIEWS
- NF-κB and the link between inflammation and cancer
- (2012) Joseph A. DiDonato et al. IMMUNOLOGICAL REVIEWS
- NK Cell Tolerance to TLR Agonists Mediated by Regulatory T Cells after Polymicrobial Sepsis
- (2012) F. Souza-Fonseca-Guimaraes et al. JOURNAL OF IMMUNOLOGY
- NF-κB as potential target in the treatment of melanoma
- (2012) Gabriele Madonna et al. Journal of Translational Medicine
- Comparative Study of Anti-Oncogenic MicroRNA-145 in Canine and Human Malignant Melanoma
- (2011) Shunsuke NOGUCHI et al. JOURNAL OF VETERINARY MEDICAL SCIENCE
- NF-κB promotes epithelial–mesenchymal transition, migration and invasion of pancreatic carcinoma cells
- (2010) Harald J. Maier et al. CANCER LETTERS
- Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
- (2010) Kai Kessenbrock et al. CELL
- The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer
- (2009) Jan M. Ehrchen et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Decreased Expression of MicroRNA-143 and -145 in Human Gastric Cancers
- (2009) Takeshi Takagi et al. ONCOLOGY
- Activation of toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors
- (2008) Y. Goto et al. MOLECULAR CANCER THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started